Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NXP800 · 1 trial · 8 indications
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Escalation | EXPERIMENTAL | Escalating doses of NXP800 administered orally once or twice daily. |
| Part B: Expansion in Ovarian Cancers Cohort 1 | EXPERIMENTAL | Subjects will be treated with NXP800 at 50 mg/day orally. |
| Part B: Expansion in Ovarian Cancers Cohort 2 | EXPERIMENTAL | Subjects will be treated with NXP800 at 75 mg/day orally. |
| Name | Type | Description |
|---|---|---|
| NXP800 | DRUG | NXP800 is an anti-neoplastic, oral small molecule. |
Part A Inclusion Criteria: * Provide written informed consent. * 18 years old or older. * Life expectancy of at least 12 weeks. * Histologically- or cytologically-confirmed, advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
NXP800 is an investigational small molecule being developed for the treatment of advanced solid tumors, including ovarian cancer subtypes such as ovarian clear cell carcinoma and ovarian endometrioid adenocarcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
NXP800 targets GCN2, a gene that encodes a kinase involved in cellular stress responses. By inhibiting GCN2, NXP800 is designed to interfere with tumor cell survival mechanisms. This target is being studied in the context of advanced solid tumors, particularly those with ARID1A gene mutations.
NXP800 is being developed by Nuvectis Pharma, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol NVCT. The company is conducting clinical trials to evaluate the safety and efficacy of NXP800 in patients with advanced cancers.
NXP800 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied in clinical trials. The drug has received Orphan Drug and Fast Track designations from the FDA for certain indications.
NXP800 is being studied in a Phase 1 clinical trial with the identifier NCT05226507. This trial is active but not recruiting and is enrolling approximately 45 patients with advanced solid tumors, including ovarian cancer subtypes. The study is being conducted in the United States and the United Kingdom.
NXP800 is the sole name provided for this investigational drug. It is not known to have any alternative names or aliases. The drug is being developed by Nuvectis Pharma, Inc. and is currently in Phase 1 trials for advanced solid tumors.